NCT06966050 Multi-center MRD Registry for Inflammatory Breast Cancer
| NCT ID | NCT06966050 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-05-05 |
| Primary Completion | 2030-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-05-05 with a primary completion date of 2030-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To collect data from participants with IBC who may have had MRD testing and may have surgery in the future.
Eligibility Criteria
Inclusion Criteria: * Female or males ≥18 years of age with the ability to understand and sign a written * Participants who have a clinical diagnosis of stage III or IV inflammatory breast cancer (IBC). * Participants who are planning to have or already completed a minimum of one blood draw for Signatera testing, for which the result and clinical data can be deposited into the study database. * Participants must be within eight months of diagnosis and have not undergone breast surgery for this diagnosis of breast cancer. * Participants must be English-speaking. Exclusion Criteria: \-
Contact & Investigator
Sadia Saleem, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT06966050 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06966050 currently recruiting?
Yes, NCT06966050 is actively recruiting participants. Contact the research team at ssaleem@mdanderson.org for enrollment information.
Where is the NCT06966050 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06966050 clinical trial?
NCT06966050 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Sadia Saleem, MD at M.D. Anderson Cancer Center. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.